• Logo
  • SBMUJournals

Association study of Retinoic Acid Related Orphan Receptor A (RORA) gene and risk of prostate disorders

Mohammad Taheri, Rezvan Noroozi, Alireza Dehghan, Golnaz Atri Roozbahani, Mehrnoosh Musavi, Mir Davood Omrani, Soudeh Ghafouri-Fard



Purpose: Prostate cancer (PCa) and benign prostate hyperplasia (BPH) are two prevalent disorders among men with considerable mortality and morbidity. Several association studies have been conducted in different populations to find genetic loci linked with these disorders. Retinoic acid-receptor-related orphan receptor alpha (RORA) codes for a transcription factor which regulates expression of several cancer-related genes. Besides, RORA has been shown to be down-regulated in PCa tissues and cell lines.

Materials and Methods: In the present study we evaluated genotype and allele frequencies of rs11639084 and rs4774388 variants within RORA gene in PCa and BPH patients compared with healthy subjects.

Results: The rs11639084 and rs4774388 alleles were not different between PCa and normal groups 95% CI: 0.52-1.24, OR = 1.04, P = .34; 95% CI: 0.48-1.33, OR = .79, P = .39 respectively. Moreover, we did not detect any significant difference in allele, genotype or haplotype frequencies of these SNPs between the other study groups.

Conclusion: The mentioned RORA variants are possibly not involved in the pathogenesis of PCa and BPH. Future studies are needed to assess the associations between other variant within this gene and PCa risk to suggest a putative mechanism for involvement of RORA in PCa.


Ghafouri-Fard S, Ousati Ashtiani Z, Sabah Golian B, Hasheminasab SM, Modarressi MH. Expression of two testis-specific genes, SPATA19 and LEMD1, in prostate cancer. Archives of medical research. 2010;41(3):195-200. doi:10.1016/j.arcmed.2010.04.003.

Taheri M, Pouresmaeili F, Omrani MD, Habibi M, Sarrafzadeh S, Noroozi R et al. Association of ANRIL gene polymorphisms with prostate cancer and benign prostatic hyperplasia in an Iranian population. Biomarkers in medicine. 2017;11(5):413-22. doi:10.2217/bmm-2016-0378.

Taheri M, Habibi M, Noroozi R, Rakhshan A, Sarrafzadeh S, Sayad A et al. HOTAIR genetic variants are associated with prostate cancer and benign prostate hyperplasia in an Iranian population. Gene. 2017;613:20-4. doi:10.1016/j.gene.2017.02.031.

Faramarzi S, Ghafouri-Fard S. Expression analysis of cancer-testis genes in prostate cancer reveals candidates for immunotherapy. Immunotherapy. 2017;9(12):1019-34. doi:10.2217/imt-2017-0083.

Moretti RM, Marelli MM, Motta M, Polizzi D, Monestiroli S, Pratesi G et al. Activation of the orphan nuclear receptor RORalpha induces growth arrest in androgen-independent DU 145 prostate cancer cells. The Prostate. 2001;46(4):327-35.

Roshan-Moniri M, Hsing M, Butler MS, Cherkasov A, Rennie PS. Orphan nuclear receptors as drug targets for the treatment of prostate and breast cancers. Cancer Treat Rev. 2014;40(10):1137-52. doi:10.1016/j.ctrv.2014.10.005.

Taheri M, Omrani MD, Noroozi R, Sarrafzadeh S, Ghafouri-Fard S, Sayad A. Retinoic acid-related orphan receptor alpha (RORA) variants and risk of breast cancer. Breast disease. 2017. doi:10.3233/BD-160248.

Truong T, Liquet B, Menegaux F, Plancoulaine S, Laurent-Puig P, Mulot C et al. Breast cancer risk, nightwork, and circadian clock gene polymorphisms. Endocrine-related cancer. 2014;21(4):629-38. doi:10.1530/erc-14-0121.

Sayad A, Noroozi R, Omrani MD, Taheri M, Ghafouri-Fard S. Retinoic acid-related orphan receptor alpha (RORA) variants are associated with autism spectrum disorder. Metabolic brain disease. 2017;32(5):1595-601. doi:10.1007/s11011-017-0049-6.

Solé X, Guinó E, Valls J, Iniesta R, Moreno V. SNPStats: a web tool for the analysis of association studies. Bioinformatics. 2006;22(15):1928-9.

Moretti RM, Montagnani Marelli M, Sala A, Motta M, Limonta P. Activation of the orphan nuclear receptor RORalpha counteracts the proliferative effect of fatty acids on prostate cancer cells: crucial role of 5-lipoxygenase. International journal of cancer. 2004;112(1):87-93. doi:10.1002/ijc.20387.

Zhu Y, McAvoy S, Kuhn R, Smith DI. RORA, a large common fragile site gene, is involved in cellular stress response. Oncogene. 2006;25(20):2901-8. doi:10.1038/sj.onc.1209314.

Ward LD, Kellis M. HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. Nucleic Acids Res. 2012;40(D1):D930-D4. doi:10.1093/nar/gkr917.

Breyer JP, Dorset DC, Clark TA, Bradley KM, Wahlfors TA, McReynolds KM et al. An expressed retrogene of the master embryonic stem cell gene POU5F1 is associated with prostate cancer susceptibility. American journal of human genetics. 2014;94(3):395-404. doi:10.1016/j.ajhg.2014.01.019.

Solt LA, Kojetin DJ, Burris TP. The REV-ERBs and RORs: molecular links between circadian rhythms and lipid homeostasis. Future Med Chem. 2011;3(5):623-38. doi:10.4155/FMC.11.9.

Gu F, Zhang H, Hyland PL, Berndt S, Gapstur SM, Wheeler W et al. Inherited variation in circadian rhythm genes and risks of prostate cancer and three other cancer sites in combined cancer consortia. International journal of cancer. 2017;141(9):1794-802. doi:10.1002/ijc.30883.

DOI: http://dx.doi.org/10.22037/uj.v0i0.4373


  • There are currently no refbacks.